Abstract: A wet wipe with a substrate having cellulosic fibers and a lotion is provided. The lotion may have between about 96.0% and about 99.5%, by weight of the lotion, of water. The lotion may have a preservative system having benzoic acid and/or a salt thereof, succinic acid and/or a salt thereof, and phytic acid and/or a salt thereof. The lotion may also have a surfactant, pH buffering system, and a pH of about 3.5 to about 5.
Type:
Grant
Filed:
May 13, 2022
Date of Patent:
May 7, 2024
Assignee:
The Procter & Gamble Company
Inventors:
Randall Glenn Marsh, Amber Grace Teufel, Julia Kuhlmann
Abstract: An 2-benzo-[3,4-b]quinolino-[b,g]indeno[1?,2?:3,4]fluoreno-[1,2-d]oxonine-5,11,16,21-tetraone compound, its synthesis, and its use as an antimicrobial agent.
Type:
Grant
Filed:
November 2, 2023
Date of Patent:
April 30, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
Abstract: A hair conditioner composition comprising: a) a fatty acid; b) a fatty alcohol; and c) an antimicrobial system comprising: i) glyceryl caprylate; and ii) one or more of 4-hydroxyacetophenone and pentylene glycol.
Type:
Grant
Filed:
June 17, 2021
Date of Patent:
April 30, 2024
Assignee:
The Procter & Gamble Company
Inventors:
Nobuaki Uehara Matsuoka, Kai Wei Kelvin Lee
Abstract: Personal care compositions for improving the appearance and/or health of skin are provided herein. In accordance with an aspect, provided is a personal care formulation comprising an alpha hydroxy acid; a beta hydroxy acid; and polyhydroxy acid comprising gluconodeltalactone. According to another aspect, a personal care formulation is provided that comprises an alpha hydroxy acid; a beta hydroxy acid; and polyhydroxy acid, wherein the personal care formulation has a weight ratio of alpha hydroxy acid to polyhydroxy acid is about 5:1 to about 1:4, and wherein the personal care formulation has a weight ratio of beta hydroxy acid to polyhydroxy acid is about 1:1 to about 1:11.
Abstract: The present invention relates to compositions and methods for reducing or eliminating wrinkles and improving skin texture and appearance. The compositions, which comprise at least one acetyl hexapeptide and a dipeptide that is optionally complexed to an amino acid, may be administered orally, sublingually, topically and/or transdermally.
Abstract: Skin hydration is necessary to maintain the epidermal barrier, minimize adverse environmental influences, and reduce cell stress. Provided herein are compounds, such as compounds of Formula (I), and pharmaceutically and cosmetically acceptable salts thereof, and compositions, methods, and uses that may be used for skin hydration. Also reported herein is a scalable method for synthesizing compounds of Formula (I). The compounds provided herein are responsible for improved skin penetration and/or retention and are therefore useful for the treatment and/or prevention of various diseases, disorders, or conditions to protect human skin.
Type:
Grant
Filed:
December 18, 2020
Date of Patent:
March 26, 2024
Assignee:
Massachusetts Institute of Technology
Inventors:
Bradley David Olsen, Allie Obermeyer, Sieun Kim Barnes, Yun Jung Yang
Abstract: Provided herein are fixed-dose combination formulations of a pharmaceutically effective amount of eflornithine together with a pharmaceutically effective amount of sulindac. Also provided are methods of use and of methods of manufacture of these formulations.
Type:
Grant
Filed:
November 15, 2022
Date of Patent:
March 12, 2024
Assignee:
Cancer Prevention Pharmaceuticals, Inc.
Inventors:
Patrick Shannon, Roberto Carlos Bravo González, Jean Ducassou
Abstract: The present invention provides a gel patch having a paste layer on a support, wherein the paste layer comprising ketoprofen or a pharmaceutically acceptable salt thereof, propylene glycol, 1-menthol, and water, wherein the mass of propylene glycol in the paste layer is 3-fold the mass of ketoprofen or less, and wherein the content of 1-menthol based on a total mass of the paste layer is 0.1 to 0.5 mass %.
Abstract: Disclosed is a topical anhydrous, homogenous pharmaceutical composition for treating skin disorder and wounds comprising cod liver oil, hempseed oil, monolaurin, medium chain triglycerides (“MCT”), free fatty acids, sea salt, and vegetable oil selected from the group consisting of red palm concentrate, coconut oil, and red palm oil and combination thereof and optionally fish collagen, ascorbyl palmitate, thickening agent, such as beeswax, red palm concentrate and cetyl ester.
Type:
Grant
Filed:
April 12, 2019
Date of Patent:
February 20, 2024
Assignee:
Omeza Holdings, Inc.
Inventors:
Griscom Bettle, III, John Harlin, Thomas Gardner
Abstract: The disclosure provides a nanoemulsion including an oil phase containing at least one cannabinoid and a water phase; wherein at least one of the oil phase and the water phase includes one or more emulsifying agents; and wherein the zeta potential of the nanoemulsion is less than about ?10 mV. Further provided are processes for preparing such nanoemulsions.
Type:
Grant
Filed:
March 1, 2021
Date of Patent:
February 13, 2024
Assignee:
NICOVENTURES TRADING LIMITED
Inventors:
Anthony Richard Gerardi, Thomas H. Poole, Steven Lee Alderman
Abstract: The invention provides various novel compositions of berberine in combination with pharmacologically active EPA and DHA, and related methods of their use in treating various diseases or disorders. The pharmaceutical compositions of the invention are useful in treating and/or preventing various diseases or disorders, including metabolic diseases or disorders such as dyslipidemia, hyperglycemia, hypertriglyceridemia, hyperlipidemia, diabetic dyslipidemia, diabetic hyperlipidemia, dyslipidemia in statin-intolerance patients, diabetes, diabetic complications, hypercholesterolemia, or obesity. Additionally, the pharmaceutical compositions of the invention are useful in treating and/or preventing atherosclerosis, heart diseases, neurodegenerative diseases, inflammation, cancers, as well as various liver diseases or disorders, such as fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cholestatic liver diseases or graft-versus-host disease of the liver.
Abstract: The invention relates to pharmaceutical compositions for parenteral administration comprising a) Ibuprofen or a pharmaceutically acceptable salt thereof, and b) a phosphate buffer.
Abstract: In an embodiment, a moisturizing composition includes a silk solution, wherein the silk solution comprises about 1% to about 10% (w/v) of pure silk fibroin-based protein fragments that are substantially devoid of sericin; hyaluronic acid; an oil or butter; and a pH adjusting agent.
Type:
Grant
Filed:
April 29, 2016
Date of Patent:
January 23, 2024
Assignee:
Evolved By Nature, Inc.
Inventors:
Gregory H. Altman, Dylan S. Haas, Kevin T. Healy
Abstract: Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that include particulate structures that are formed from PGS, cerivastatin and everolimus. The particulate structures are configured to modulate inflammation of damaged cardiovascular tissue in vivo by increasing expression of Kruppel like factor 2 (KLF-2), whereby localized expression of monocyte chemoattractant protein 1 (MCP-1) and C-C chemokine receptor type 2 (CCR2) is inhibited at transcriptional and translational levels as a function of the KLF-2 modulation.
Abstract: The present disclosure relates to medical devices containing time-release drug substance, and more particularly, to medical tubing, catheters, stents, cables (including fiber optic cables), pills, capsules, sheaths, threads, clamps, sutures, and endotracheal devices. The invention also generally relates to a method for extruding multiple laminated flow streams using microlayer coextrusion to create these various time-release drug delivery products.
Type:
Grant
Filed:
June 23, 2020
Date of Patent:
December 26, 2023
Assignee:
Guill Tool & Engineering Co., Inc.
Inventors:
Richard Guillemette, Robert Peters, Christopher Hummel
Abstract: Compositions, methods of manufacturing compositions, methods of protecting against respiratory problems including coronavirus and coronavirus-associated severe acute respiratory syndrome (SARS) in humans and animals, are provided. Compositions comprising inorganic nitrate used for improving nitric oxide levels, improving health and/or reducing symptoms of SARS are provided. The compositions and methods are applicable for subjects experiencing SARS, and for protecting non-infected subjects against SARS. Compositions and methods for improving nitric oxide levels in a subject disclosed herein comprise administration of compositions comprising inorganic nitrate such as potassium nitrate or sodium nitrate optionally combined with ascorbate.
Abstract: A pharmaceutical composition for treating skin infections is described herein. A method using a pharmaceutical composition for treating skin infections is described herein. A pharmaceutical composition for treating skin infections may comprise, in 100 parts of the composition, 1-99 parts of a pharmaceutically acceptable excipient; 99-1 parts of a keratolytic; 99-1 parts ethyl pyruvate; and 99-1 parts povidone iodine. A method for treating skin infections may comprise topical application of a composition to an infected skin cell for a treatment period.
Abstract: A method of manufacturing a flowable and dispersible powder includes solubilizing a lipophilic substance in a terpene to form a mixture and treating the mixture to form a nanoemulsion dispersed in an aqueous solution. The aqueous solution includes at least one functional excipient. The nanoemulsion is then spray dried, thereby evaporating first the aqueous portion and then the terpene to form a dry powder formed from solid particles comprising the lipophilic substance.
Type:
Grant
Filed:
June 5, 2019
Date of Patent:
December 5, 2023
Assignee:
FLURRY POWDERS, LLC
Inventors:
Andrew John Boeckl, David Edward Cookson
Abstract: A method of treating a gastrointestinal disorder includes administering to a patient an effective amount of a multiparticulate dosage form including a plurality of individual spheroidal enteric coated cores having a diameter of 0.1 mm to 3 mm. The individual spheroidal enteric coated cores have (a) a core including menthol, (b) a proteinaceous subcoating over the core, and (c) an enteric coating over the proteinaceous subcoating. The multiparticulate dosage form is configured to release most of the menthol in the area of the GI tract where the inflammation is occurring.
Abstract: Cannabinoid-loaded formulations are characterized by including 0.5 wt. % to 20 wt. % medium chain triglycerides, one or more hydrophilic surfactants, one or more co-surfactants and 0.1 wt. % or more of at least one cannabinoid. The formulations are in microemulsion form, and are fully dilutable by an aqueous diluent.
Type:
Grant
Filed:
September 28, 2017
Date of Patent:
November 21, 2023
Assignee:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.